![]() |
市場調查報告書
商品編碼
1494683
基因生物標記市場:按產品類型、適應症和最終用戶分類 - 全球預測 2024-2030Genomic Biomarker Market by Product (Consumables, Services, Software), Type (Predictive Biomarkers, Prognostic Biomarkers), Disease Indication, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年基因生物標記市場規模為44億美元,預計2024年將達46.7億美元,2030年將達到69.2億美元,複合年成長率為6.67%。
基因生物標記是DNA或RNA分子,用於檢查基因與環境之間的複雜關係,大大增強了對健康、疾病和農產品的理解和管理。這些生物標記在早期疾病診斷和風險評估中發揮著至關重要的作用,使得在症狀出現之前更容易識別潛在的健康問題,例如癌症和心血管疾病。基因生物標記提供個人化醫療,允許根據每個人的基因圖譜客製化治療,最佳化治療效果並最大限度地減少副作用。製藥領域在開發特異性針對疾病分子基礎的標靶藥物中從基因生物標記中受益匪淺。在農業中,基因生物標記能夠培育出提高產量並抵抗環境壓力的作物品種。基因生物標記廣泛應用於農業研究、醫療保健和農業。隨著基因組標記在個人化醫療中的應用不斷擴大,醫療保健和製藥領域對基因生物標記的需求正在迅速增加。此外,政府對基因生物標記研究和開發的監管支持不斷增加,正在推動對先進、更有效的基因生物標記的需求。然而,與這些生物標記開發相關的技術限制阻礙了需求。此外,將機器學習和人工智慧整合到基因組研究中將增強基因生物標記的預測能力。
主要市場統計 | |
---|---|
基準年[2023] | 44億美元 |
預測年份 [2024] | 46.7億美元 |
預測年份 [2030] | 69.2億美元 |
複合年成長率(%) | 6.67% |
區域洞察
由於醫療基礎設施的改善和生物醫學研究投資的大幅增加,美洲,尤其是北美,對基因生物標記的需求強勁。由於該地區癌症和心血管疾病等慢性疾病的高盛行率,個人化醫療方法正在擴大基因生物標記的應用。此外,研究機構和生技公司之間的持續合作將加強基因生物標記的創新,支持政府的基因組研究資助政策,並規範進展以擴大馬蘇地區的需求。由於醫療保健和診斷領域的快速擴張,該地區的基因生物標記市場正在快速成長。在中國、日本、韓國等國家,生物技術領域正在快速發展,對基因生物標記有強烈需求。醫療保健支出的增加、個人化醫療意識的提高以及公共和私人對基因組研究投資的增加是關鍵促進因素。由於先進醫療保健系統和次世代定序儀技術的普及,歐洲和中東地區正在呈現快速成長。在歐盟 (EU),由於政府對基因組研究和國家間合作研究的資助,基因生物標記的引入顯著擴大。由於更加重視改善醫療保健系統以及增加對醫療保健產業的外國投資,非洲地區具有成長潛力。
FPNV定位矩陣
FPNV 定位矩陣對於評估基因生物標記市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對基因生物標記市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在基因生物標記市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[194 Pages Report] The Genomic Biomarker Market size was estimated at USD 4.40 billion in 2023 and expected to reach USD 4.67 billion in 2024, at a CAGR 6.67% to reach USD 6.92 billion by 2030.
Genomic biomarkers are DNA or RNA molecules that are used to examine the complex relationships between genetics and the environment and significantly enhance understanding and management of health, diseases, and agricultural outputs. These biomarkers play a pivotal role in early disease diagnosis and risk assessment, facilitating the identification of potential health issues such as cancer and cardiovascular diseases before they manifest symptoms. Genomic biomarkers offer personalized medicine and enable the customization of treatments to each individual's genetic profile, optimizing therapy effectiveness and minimizing adverse effects. The pharmaceutical sector benefits immensely from genomic biomarkers in the development of targeted medications that specifically address the molecular basis of diseases. In agriculture, they enable the breeding of crop varieties with enhanced yields and resistance to environmental stresses. Genomic biomarkers are widely used in agricultural research, healthcare, and farming practices. The growing applications of genomic markers for personalized medicine are surging the need for genomic biomarkers in the healthcare and pharmaceutical sectors. Additionally, the growing regulatory support by the governments for research and development of genomic biomarkers is driving the demand for advanced and more effective genomic biomarkers. However, technical limitations associated with the development of these biomarkers hinder the demand. Moreover, the integration of machine learning and AI with genomic studies enhances the predictive ability of genomic biomarkers.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 4.40 billion |
Estimated Year [2024] | USD 4.67 billion |
Forecast Year [2030] | USD 6.92 billion |
CAGR (%) | 6.67% |
Regional Insights
In the Americas, particularly North America, is exhibiting a robust demand for genomic biomarkers with the well-established healthcare infrastructure and a significant increase in investments in biomedical research. With a high prevalence of chronic diseases such as cancer and cardiovascular diseases within the region, personalized medicine approaches are thus increasing the application of genomic biomarkers. Moreover, ongoing collaborations between research institutes and biotechnology companies enhance the innovation of genomic biomarkers, support government policies on genomics research funds, and regulate advancements to expand the demand within the region. This region is experiencing rapid growth in the genomic biomarker market with the surging expansion of the healthcare and diagnostic sectors. Countries such as China, Japan, and South Korea have robust needs for genomic biomarkers due to their fast-growing biotech sectors. Rising healthcare expenditure, rising awareness about personalized medicine, and an increase in public and private investment in genomic research are important drivers. Europe and the Middle East regions show rapid growth driven by advanced healthcare systems and widespread adoption of next-generation sequencing technologies. Government funding in genomics and collaborations across countries in the European Union are significantly growing the adoption of genomic biomarkers. There is potential growth in the African region due to an increasing focus on improving healthcare systems and rising foreign investments in the healthcare sector.
Market Insights
The market dynamics represent an ever-changing landscape of the Genomic Biomarker Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Genomic Biomarker Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Genomic Biomarker Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Bio-Rad Introduces Revolutionary Multiplexed Digital PCR Assay for Enhanced Breast Cancer Research
Bio-Rad Laboratories, Inc. unveiled its groundbreaking ddPLEX ESR1 Mutation Detection Kit. his kit marks a significant advance in the oncology sector by offering an ultrasensitive, multiplexed digital PCR assay designed to detect, differentiate, and quantitatively assess seven critical ESR1 mutations from a single sample. This development expands Bio-Rad's portfolio in digital PCR solutions and strengthens its commitment to supporting oncology researchers in biomarker discovery and clinical trials, thereby improving patient care continuity and treatment efficacy. [Published On: 2024-04-01]
Biofidelity's Introduction ASPYRE-Lung RUO Reagents for Enhanced and Rapid Genomic Biomarker Analysis
Biofidelity unveiled the ASPYRE-Lung RUO, a cutting-edge reagent product designed to simplify and expedite the detection of genomic biomarkers in labs globally. The ASPYRE-Lung technology uses standard PCR instruments already present in most laboratories, eliminating the need for specialized staff or complex setups. Its high sensitivity facilitates the use of tissue samples with minimal tumor content, considerably lowering the threshold compared to traditional assays. The ASPYRE-Lung RUO is poised to revolutionize diagnostic tests, ensuring high-quality results with quick turnarounds for diverse research applications. [Published On: 2023-12-06]
Illumina's Breakthrough in Oncology TruSight Oncology 500 ctDNA v2 Enhances Solid Tumor Genomic Profiling
Illumina Inc. introduced the latest version of its liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). This cutting-edge research tool offers noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA), providing critical data when traditional tissue sample testing is not feasible. As Illumina gears up to integrate automation in their assays, this innovation stands poised to redefine the landscape of tumor profiling, rendering it an increasingly indispensable tool in precision oncology. [Published On: 2023-11-01]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Genomic Biomarker Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Genomic Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocrates Life Sciences AG, Biostarks Laboratories SA, Bruker Corporation, CD Genomics, Charles River Laboratories, Inc., DH Life Sciences, LLC., Elo Health, Inc., Eurofins Scientific corporation, F. Hoffmann-La Roche Ltd, Illumina Inc., Merck KGaA, Myriad Genetics, Inc, Owkin, Inc, and Thermo Fisher Scientific company.
Market Segmentation & Coverage